Skip to content
drillr.ai

SOPH

SOPHiA GENETICS S.A.

NASDAQ · CHHealthcareMedical - Healthcare Information Services
$6.33+7.84%

Price as of Jul 20, 2026

SOPH news

SOPHiA GENETICS S.A. news

A server-rendered, paginated timeline of the latest available company news.

  1. SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting

    SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting PR Newswire ROLLE, Switzerland, June 22, 2026 Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026 ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual Gene

    PR Newswire ·

  2. SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

    SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire BOSTON and ROLLE, Switzerland, June 19, 2026 BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before

    PR Newswire ·

  3. SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

    SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE, Switzerland, June 16, 2026 BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, befor

    PR Newswire ·

  4. SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

    SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE, Switzerland, June 16, 2026 BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the p

    PR Newswire ·

  5. SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

    SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center PR Newswire NEW YORK, June 4, 2026 SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology NEW YORK, June 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4703740-1&h=270587349&u=https%3A%2F%2Fwww.sophiagenetics.com%2F&a=SOPHiA+GENETICS) (NASDAQ: SOPH) today announced that the compan

    PR Newswire ·

  6. Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

    Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. PR Newswire LONDON, May 13, 2026 LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first (https://edge.pr

    PR Newswire ·

  7. SOPHiA GENETICS Reports First Quarter 2026 Results

    SOPHiA GENETICS Reports First Quarter 2026 Results PR Newswire BOSTON and ROLLE, Switzerland, May 5, 2026 BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. (https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.html) First Quarter 2026 Financial Results * Revenue was $21.7 million, up 22% year-over-year * Gross marg

    PR Newswire ·

  8. SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference

    BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday, March 4, 2026, at 10:30 am EST / 4:30 pm CET. A live audio webcast of the fireside

    PR Newswire ·